Home › Funds › Bellevue Group AG › KRYS
Bellevue Group AG position in KRYS
KRYSTAL BIOTECH INC · Health Care
Bellevue Group AG reported holding 77,530 shares of KRYS (KRYSTAL BIOTECH INC) in its Q2 2026 13F filing — a position valued at US$28.8M, representing 0.61% of its reported portfolio and ranking #40 among its reported holdings. Bellevue Group AG has disclosed KRYS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Bellevue Group AG's KRYS position evolved
Bellevue Group AG first disclosed a stake in KRYS in Q3 2023 at 12,500 shares (US$1.4M). The position peaked in Q1 2026 at 481,785 shares, worth US$124.5M. Across 12 filings, Bellevue Group AG increased the stake 5 time(s), trimmed it 6 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 77,530 shares valued at US$28.8M — a reduction of -404,255 shares quarter over quarter.. Notable position changes include a 53% trim in Q2 2025 (shares rose 28% over the following quarter), a 31175% increase in Q4 2025 (shares rose 5% over the following quarter), a 84% trim in Q2 2026 (shares fell 11% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 12.50K | $1.45M | New |
| Q4 2023 | 8.00K | $992.48K | Reduce |
| Q1 2024 | 4.81K | $855.84K | Reduce |
| Q2 2024 | 4.20K | $770.92K | Reduce |
| Q3 2024 | 4.78K | $869.92K | Add |
| Q4 2024 | 5.05K | $790.66K | Add |
| Q1 2025 | 2.65K | $477.80K | Reduce |
| Q2 2025 | 1.25K | $171.82K | Reduce |
| Q3 2025 | 1.31K | $231.61K | Add |
| Q4 2025 | 410.32K | $101.16M | Add |
| Q1 2026 | 481.79K | $124.45M | Add |
| Q2 2026 | 77.53K | $28.82M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KRYS and 13F data
KRYS (KRYSTAL BIOTECH INC) is a Health Care company. 49 other funds we track also report a position in KRYS — the largest reported positions include Avoro Capital Advisors LLC (US$1.07B), Soleus Capital Management, L.P. (US$349.1M), Hood River Capital Management LLC (US$246.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KRYS
- Avoro Capital Advisors LLC 2.89M sh · $1.07B · Q2 2026
- Soleus Capital Management, L.P. 939.25K sh · $349.09M · Q2 2026
- Hood River Capital Management LLC 663.38K sh · $246.56M · Q2 2026
- Redmile Group, LLC 632.00K sh · $234.90M · Q2 2026
- WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC 570.15K sh · $211.91M · Q2 2026
- Frazier Life Sciences Management, L.P. 481.31K sh · $178.89M · Q2 2026
- VESTOR CAPITAL, LLC 700.91K sh · $78.19M · Q2 2026
- BRAIDWELL LP 128.97K sh · $47.94M · Q2 2026
More on Bellevue Group AG
FAQ
How long has Bellevue Group AG held KRYS?
Bellevue Group AG has disclosed KRYS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.
What is Bellevue Group AG's current position in KRYS?
As of Q2 2026, Bellevue Group AG holds 77.53K shares of KRYS (KRYSTAL BIOTECH INC), valued at $28.82M, representing 0.61% of its reported portfolio and ranking #40.
Has Bellevue Group AG been buying or selling KRYS?
In the latest 13F filing (Q2 2026), Bellevue Group AG reduced its position in KRYS. The position peaked in Q1 2026 at 481.79K shares.
Which other funds hold KRYS?
Other major institutional holders of KRYS include Avoro Capital Advisors LLC, Soleus Capital Management, L.P., Hood River Capital Management LLC, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.